All Articles

With myopia rates soaring, HOYA's MiYOSMART iQ lens enters Canada with unprecedented clinical results, signaling a major strategic shift in pediatric vision care.

By assembling a 'dream team' of scientific advisors, INmune Bio isn't just advancing a drug; it's fortifying the very structure of cell therapy development.

Altria touts shareholder returns and narrows profit guidance, but a deeper look reveals weakening Marlboro sales and a high-stakes, uncertain pivot to smoke-free.

SunCoke Energy's stellar Q2 results reveal a masterstroke in strategy, with its Phoenix acquisition driving record growth and diversifying the firm's future.

With a lens clinically shown to stop nearsightedness in 9 of 10 kids, HOYA isn't just launching a product; it's making a power play in a blurry market.

eBay's acquisition of Depop isn't just about clothes; it's a high-stakes play for relevance, a bid to capture the circular economy, and a test of survival.

A startup is using real neurons to discover software that slashes AI costs. We analyze the tech, the market, and the profound implications of this new frontier.

AMG's record Q2 results showcase a masterclass in strategic evolution. A deep dive into alternative investments is fueling massive growth and a disciplined capital return strategy.

Amid record revenues, Martin Marietta's blockbuster deal for Lhoist North America signals a bold pivot beyond construction into industrial minerals.

As Dollar General preps its Q2 earnings, all eyes are on what its results will reveal about inflation, consumer shifts, and the health of the U.S. economy.

A breakthrough in memory from Innodisk promises a 60% speed boost, tackling the bottleneck that slows AI and setting the stage for next-gen computing.

The luxury outfitter's Q1 results beat expectations, yet a closer look reveals a brand grappling with softening store traffic and a looming trade war.

Scorpio Tankers' record Q2 earnings are just the surface. Beneath the windfall lies a masterclass in capital strategy and fleet renewal for a new era.

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

A single partner default triggers a massive loss at Coastal Financial, testing its high-growth Banking-as-a-Service model and raising questions about hidden risks.

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Cinemark shattered records with its first-ever billion-dollar quarter, proving strategic investments in premium experiences can defy the streaming era.

A 5,000km caravan from Wuhan to Kyrgyzstan signals more than a marketing stunt. It's a strategic push by China's automotive heartland to dominate new markets.

A key hire reveals how a legacy bank is leveraging specialized lending and deep community ties to capture one of the nation's most dynamic markets.

A new report reveals a perfect storm: 100% of tested AI apps are vulnerable, logic flaws are exploding, and cloud assets are critically exposed.